Cangene Receives WinRho Approval

Cangene Corp.‘s wholly owned subsidiary, Cangene Europe Limited, has received marketing authorization approval for WinRho 1500 LQ in Portugal from the National Authority of Medicines and Health Products, IP (INFARMED).

The company has received a national license to market the product in Portugal for two indications: to prevent Rh₀(D) immunization women that are in Rh₀(D) negative, and to treat Rh₀(D) negative patients after incompatible Rh₀(D) positive blood transfusions or other products containing erythrocytes antigens.

John A. Sedor, Cangene’s president and chief executive officer, said: “Today’s approval is a milestone for Cangene and significant news for expectant mothers and other Rh-negative patients in Portugal. By bringing WinRho to Portugal, we have reestablished a foothold in Europe as we drive the growth of Cangene’s flagship product in markets outside of North America.”

The product will be distributed nationally in Portugal by a third party distributor on behalf of Cangene.

Cangene’s contract manufacturing group will be at table #140 at Contract Pharma’s Contracting & Outsourcing Conference & Tabletop Exhibition on Sept. 19! For more information, visit the conference site!